Act Capital Management, LLC reported 58 positions worth $151.51M for the quarter ended Jun 30, 2026, up 19.4% on the prior quarter. It opened 17 new positions, added to 15, trimmed 12 and exited 13. Its largest holding is Krystal Biotech, Inc. at 11% of the portfolio.
Reported 13F market value at each quarter end. A change mixes trading with price moves in the positions held.
Dollar value of shares bought and sold each quarter, at that quarter’s price. It counts trading only, not price changes.
How many positions were opened, added to, trimmed or closed each quarter.
Share of reported value in each sector at every quarter end.
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| TSLA Tesla, Inc. | +10.8K | – | $4.54M | 3% |
| ASTS AST SpaceMobile, Inc. | +43.5K | – | $3.87M | 2.55% |
| ABVX Abivax S.A. | +26.1K | +36.8% | $3.48M | 8.53% |
| PVLA Palvella Therapeutics, Inc. | +22.5K | – | $3.44M | 2.27% |
| ARWR Arrowhead Pharmaceuticals, Inc. | +27.6K | +33.5% | $2.25M | 5.92% |
| NBIS Nebius Group N.V. | +6,800 | – | $1.88M | 1.24% |
| AMBA Ambarella Inc | +16.0K | – | $1.37M | 0.906% |
| NUVB Nuvation Bio Inc. | +230.0K | +79.3% | $1.31M | 1.95% |
| NKTR Nektar Therapeutics | +18.4K | +26.0% | $1.28M | 4.11% |
| CBRS Cerebras Systems Inc. | +5,600 | – | $1.24M | 0.817% |
| Holding | Change | Change % | Trade Value | Weight |
|---|---|---|---|---|
| KRYS Krystal Biotech, Inc. | -15.5K | -25.6% | $5.75M | 11.04% |
| AMZN Amazon Com Inc | -20.1K | -60.9% | $4.79M | 2.03% |
| ALMS Alumis Inc. | -122.7K | -70.4% | $3.45M | 0.958% |
| CELC Celcuity Inc. | -29.5K | -32.2% | $3.09M | 4.29% |
| AAOI Applied Optoelectronics, Inc. | -19.9K | -76.8% | $2.95M | 0.587% |
| MU Micron Technology Inc | -1,300 | -86.7% | $1.50M | 0.152% |
| CYTK Cytokinetics Inc | -17.0K | -26.4% | $1.45M | 2.67% |
| STAA Staar Surgical Co | -55.5K | -100.0% | $1.04M | Exited |
| S SentinelOne, Inc. | -54.3K | -100.0% | $699.38K | Exited |
| LITE Lumentum Holdings Inc. | -900 | -100.0% | $632.48K | Exited |
| Holding | Shares | Trade Value | Weight |
|---|---|---|---|
| TSLA Tesla, Inc. | +10.8K | $4.54M | 3% |
| ASTS AST SpaceMobile, Inc. | +43.5K | $3.87M | 2.55% |
| PVLA Palvella Therapeutics, Inc. | +22.5K | $3.44M | 2.27% |
| NBIS Nebius Group N.V. | +6,800 | $1.88M | 1.24% |
| AMBA Ambarella Inc | +16.0K | $1.37M | 0.906% |
| CBRS Cerebras Systems Inc. | +5,600 | $1.24M | 0.817% |
| DFTX Definium Therapeutics, Inc. | +25.0K | $1.18M | 0.776% |
| NOK Nokia Corp | +82.0K | $1.09M | 0.719% |
| MLYS Mineralys Therapeutics, Inc. | +28.1K | $758.14K | 0.5% |
| PLTR Palantir Technologies Inc. | +5,500 | $641.69K | 0.424% |
| Holding | Shares Sold | Trade Value | Prior Weight |
|---|---|---|---|
| STAA Staar Surgical Co | -55.5K | $1.04M | 0.818% |
| S SentinelOne, Inc. | -54.3K | $699.38K | 0.551% |
| LITE Lumentum Holdings Inc. | -900 | $632.48K | 0.498% |
| CRCL Circle Internet Group, Inc. | -6,000 | $572.46K | 0.451% |
| NVDA Nvidia Corp | -2,800 | $488.32K | 0.385% |
| REPL Replimune Group, Inc. | -61.5K | $470.48K | 0.371% |
| OLMA Olema Pharmaceuticals, Inc. | -25.0K | $372.75K | 0.294% |
| INCY Incyte Corp | -2,000 | $188.24K | 0.148% |
| CAPR Capricor Therapeutics, Inc. | -5,000 | $152.00K | 0.12% |
| VPG Vishay Precision Group, Inc. | -3,000 | $130.26K | 0.103% |
| # | Activity | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| 1 | KRYS Krystal Biotech, Inc. | Healthcare | 45.0K | $16.73M | 11.04% | -15.5K | -25.6% | Reduced | 0.15% |
| 2 | TGTX Tg Therapeutics, Inc. | Healthcare | 251.0K | $13.79M | 9.1% | +2,000 | +0.8% | Added | 0.16% |
| 3 | ABVX Abivax S.A. | Healthcare | 97.0K | $12.93M | 8.53% | +26.1K | +36.8% | Added | 0.14% |
| 4 | CVX Chevron Corp | Energy | 75.0K | $12.43M | 8.21% | 0 | 0.0% | Unchanged | 0% |
| 5 | XOM ExxonMobil Holdings Corp | Energy | 78.5K | $10.73M | 7.08% | +8,500 | +12.1% | Added | 0% |
| 6 | ARWR Arrowhead Pharmaceuticals, Inc. | Healthcare | 110.1K | $8.97M | 5.92% | +27.6K | +33.5% | Added | 0.08% |
| 7 | VKTX Viking Therapeutics, Inc. | Healthcare | 209.3K | $8.16M | 5.39% | 0 | 0.0% | Unchanged | 0.18% |
| 8 | CELC Celcuity Inc. | Healthcare | 62.2K | $6.50M | 4.29% | -29.5K | -32.2% | Reduced | 0.11% |
| 9 | NKTR Nektar Therapeutics | Healthcare | 89.3K | $6.23M | 4.11% | +18.4K | +26.0% | Added | 0.27% |
| 10 | TSLA Tesla, Inc. | Consumer Discretionary | 10.8K | $4.54M | 3% | +10.8K | – | New | 0% |
| 11 | CYTK Cytokinetics Inc | Healthcare | 47.5K | $4.05M | 2.67% | -17.0K | -26.4% | Reduced | 0.03% |
| 12 | ASTS AST SpaceMobile, Inc. | Communication Services | 43.5K | $3.87M | 2.55% | +43.5K | – | New | 0.01% |
| 13 | PVLA Palvella Therapeutics, Inc. | Healthcare | 22.5K | $3.44M | 2.27% | +22.5K | – | New | 0.16% |
| 14 | AMZN Amazon Com Inc | Consumer Discretionary | 12.9K | $3.07M | 2.03% | -20.1K | -60.9% | Reduced | 0% |
| 15 | NUVB Nuvation Bio Inc. | Healthcare | 520.0K | $2.95M | 1.95% | +230.0K | +79.3% | Added | 0.15% |
Tip. Select a row to see that position’s full history at Act Capital Management.
As of its Q2 2026 13F filing, Act Capital Management, LLC’s five largest positions were Krystal Biotech, Inc. (KRYS) at 11.0%, Tg Therapeutics, Inc. (TGTX) at 9.1%, Abivax S.A. (ABVX) at 8.5%, Chevron Corp (CVX) at 8.2%, ExxonMobil Holdings Corp (XOM) at 7.1% of the reported portfolio.
Act Capital Management, LLC reported a 13F portfolio worth $151.51M across 58 positions for Q2 2026. That is up 19.4% from the previous quarter.
Its largest purchases by value were Tesla, Inc. ($4.54M), AST SpaceMobile, Inc. ($3.87M), Abivax S.A. ($3.48M). It opened 17 new positions.
Its largest sales by value were Krystal Biotech, Inc. ($5.75M), Amazon Com Inc ($4.79M), Alumis Inc. ($3.45M). It exited 13 positions entirely.
From the Form 13F-HR reports Act Capital Management, LLC files with the SEC each quarter, within 45 days of quarter end. A 13F lists long positions in US-listed equities and options; it excludes short positions, cash, bonds and most non-US holdings.
13F data reflects long positions in US-listed equities and options as reported to the SEC up to 45 days after quarter end. It excludes short positions, cash, bonds and most non-US securities, so it is not a complete picture of a manager’s assets.